Yup. They did seem to try to make the groups uniform though.
I haven't read it carefully yet, but one thing that jumped out at me was:
"The pattern of statin use in our study, where 77 % of statin users used simvastatin [Zocor], may be different from current statin utilization trends. Data from the private sector indicate that the use of atorvastatin [Liptor] in certain markets may be as high as 48 %, and that rosuvastatin [Crestor] use has risen to 65 % in some markets. 78,79"
Is it a function of the kind of statin used? They don't seem to know. I'm on a generic Pravachol (20 mg).
Another is, they lumped the "low" and "moderate" statin uses together in one group and compared them to the "high" statin users in another group. Why? Does the risk scale with dose? Hard to know in a quick scan.
If you (or anyone else) want a copy of the paper, send an e-mail to anotherscott.stuff round thingy gmail dot com. It's 12 pages of small print.
Cheers,
Scott.
"The pattern of statin use in our study, where 77 % of statin users used simvastatin [Zocor], may be different from current statin utilization trends. Data from the private sector indicate that the use of atorvastatin [Liptor] in certain markets may be as high as 48 %, and that rosuvastatin [Crestor] use has risen to 65 % in some markets. 78,79"
Is it a function of the kind of statin used? They don't seem to know. I'm on a generic Pravachol (20 mg).
Another is, they lumped the "low" and "moderate" statin uses together in one group and compared them to the "high" statin users in another group. Why? Does the risk scale with dose? Hard to know in a quick scan.
If you (or anyone else) want a copy of the paper, send an e-mail to anotherscott.stuff round thingy gmail dot com. It's 12 pages of small print.
Cheers,
Scott.